Stephen C. DeRosa
M.D., Stanford University, School of Medicine, 1990.
B.S., Columbia University, Chemical Engineering, 1983.
My research focuses on the flow cytometric characterization of T cells induced by candidate T cell vaccines tested within the HIV Vaccine Trials Network (HVTN). We have developed assays that examine multiple T cell markers and functions simultaneously. An ultimate goal of this research is to identify the characteristic features of effective immune responses. This goal may not be achievable until larger phase II and III efficacy trials are performed, but in the interim, we use these assays to compare T cells induced by different vaccine regimens. Recent studies in our laboratory related to the failure of the vaccine tested in the Step trial have resulted in a broader examination of the potential impact of vaccination on the immune system. We are examining T cells that are specific for the vaccine vector. We are also developing methods to identify regulatory or suppressive T cells that can potentially be induced by vaccination.
International Society for Analytical Cytology
Assistant Professor, University of Washington, Virology
COMPASS identifies T-cell subsets correlated with clinical outcomes.. Nature biotechnology.. 2015.
Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates.. Molecular therapy : the journal of the American Society of Gene Therapy. 23(5):943-51.. 2015.
Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation.. AIDS (London, England). 29(13):1597-606.. 2015.
OMIP-025: evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining.. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 87(4):289-92.. 2015.
Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.. Journal of immunological methods.. 2014.
Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells.. Journal of virological methods. 199C:17-24.. 2014.
High-throughput flow cytometry data normalization for clinical trials.. Cytometry. Part A : the journal of the International Society for Analytical Cytology.. 2013.
HIV-1-Specific Enzyme-Linked Immunosorbent Spot Assay Responses in HIV-1-Exposed Uninfected Partners in Discordant Relationships Compared to Those in Low-Risk Controls.. Clinical and vaccine immunology : CVI. 19(11):1798-805.. 2012.
Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity.. Proceedings of the National Academy of Sciences of the United States of America. 109(50):E3503-12.. 2012.
OMIP-014: Validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining.. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 81(12):1019-21.. 2012.
Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.. Journal of immunological methods. 382(1-2):117-28.. 2012.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86.. 2012.
Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay.. Journal of visualized experiments : JoVE. (67):e4302.. 2012.
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.. PloS one. 7(7):e41832.. 2012.
HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable.. Journal of immunology (Baltimore, Md. : 1950). 187(6):3391-3401.. 2011.
Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa.. Journal of acquired immune deficiency syndromes (1999). 57(2):92-100.. 2011.
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.. The Journal of infectious diseases. 203(8):1165-73.. 2011.
Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes.. Journal of clinical immunology. 30(5):703-22.. 2010.